StockMarketWire.com - Brain health company IXICO posts a net loss after tax of £2.3m for the 16 months to the end of September against to a net profit after tax of £0.5m for the year ended 31 May 2013. It says this was as planned and was due to investments in infrastructure and headcount.

IXICO said that during the period it became a public company and continued its evolution in the emerging and fast moving digital healthcare market with a focus on brain health. Contracts were signed with four significant new customers in a range of disease indications. IXICO says it has now been awarded contracts by nine of the top 15 global pharmaceutical companies.

Chief executive Derek Hill said: "I am delighted to report a transformational 16 month period for IXICO in which its shares became publicly listed and we continued our evolution in the emerging and fast moving digital healthcare market with a focus on brain health.

"We are seeing growth in our order book for our clinical trials services business and the potential for more strategic partnerships with pharmaceutical companies using our digital technology platform. Our technologies under development are focused on the opportunity to improve the care of patients by supporting faster and more accurate diagnosis and, critically, the post-diagnosis management of those patients.

"We are also evaluating accretive technologies and business services which together with the development of existing and new business initiatives will create shareholder value and we remain excited about the future prospects for the company."








Story provided by StockMarketWire.com